Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Share News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 676.50
Bid: 675.50
Ask: 677.00
Change: 2.50 (0.37%)
Spread: 1.50 (0.222%)
Open: 688.50
High: 688.50
Low: 673.00
Prev. Close: 674.00
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Haleon appoints Tate & Lyle's finance chief as CFO from November

Wed, 24th Apr 2024 09:15

(Alliance News) - Haleon PLC on Wednesday said it has appointed Tate & Lyle PLC's Dawn Allen as chief financial officer.

Weybridge, Surrey-based consumer healthcare company Haleon said Allen will leave her current role as CFO at London-based sweetener and food ingredients supplier Tate & Lyle and join Haleon on October 28, before joining the board and assuming the role of Haleon CFO from November 1.

The appointment follows Tobias Hestler informing the Haleon board that he will step down as CFO to "better balance work demands with the management of a long-term health condition", Haleon said.

Hestler will resign from the board on November 1, before remaining with Haleon until the end of the year.

Tate & Lyle noted the timing of Allen's departure will allow it to close out its half-year results ending September 30 under her financial leadership, while it has begun a process to appoint a successor.

A further announcement will be made "in due course", Tate & Lyle said.

Prior to joining Tate & Lyle, Allen had a 25-year career at Mars Inc, where she was most recently global CFO and vice president for Global Transformation.

Haleon Chief Executive Officer Brian McNamara said: "She has a proven track record as a CFO with extensive consumer and international experience and will be a great addition to our executive team. I want to take this opportunity to thank Tobias for his significant contribution in creating Haleon as a standalone business and for the close partnership over the last few years. He has played a critical role in shaping and building Haleon's foundations and putting us on a path for long-term success.

Tate & Lyle CEO Nick Hampton commented: "During her time at Tate & Lyle, Dawn has played a key role in maintaining strong financial discipline across the business, and leaves behind a proven team that will continue to support the delivery of our growth-focused strategy."

Shares in Haleon were up 0.9% to 335.62 pence each in London on Wednesday morning, while Tate & Lyle shares were down 0.5% to 642.00p each.

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
12 Feb 2014 17:15

MARKET COMMENT: Pound Rallies To 10-Day High As BoE Boost UK Growth Forecasts

LONDON (Alliance News) - UK stocks indices have closed flat Wednesday at the end of a relatively subdued session for equities. Meanwhile the pound made its strongest gains of the year against both the dollar and the euro after the Bank of England increased its economic growth forecasts for UK.Read more

12 Feb 2014 16:12

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
12 Feb 2014 06:30

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
11 Feb 2014 16:46

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
11 Feb 2014 06:17

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
10 Feb 2014 16:06

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
10 Feb 2014 06:40

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
7 Feb 2014 17:08

London close: Strategists surprised by recent losses in markets

- Mixed US employment data - Barclays: Fed could refrain from tapering in March - Persimmon and LSE shares power ahead - NIESR: MPC will not raise rates until quarter two of 2015 techMARK 2,790.30 +0.40% FTSE 100 6,571.68 +0.20% FTSE 250 15,865.12 +0.48% The FTSE 100 managed to end the day in the

Read more
7 Feb 2014 16:22

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
7 Feb 2014 12:22

Broker tips: Shire, Tate & Lyle, Aquarius Platinum, Acal

Jefferies has kept its 'buy' rating for pharmaceuticals group Shire saying that it still sees 'attractive growth', but was disappointed by the outcome of clinical trials for the company's major depressive disorder (MDD) treatment, Vyvanse. "We were more optimistic for expanded use of Vyvanse in maj

Read more
7 Feb 2014 11:41

London midday: Stocks flat as investors await US data with caution

- Markets flat ahead of US jobs report - Stocks pause after ECB-inspired rally on Thursday - Data disappoints from China, UK, Germany techMARK 2,788.33 +0.33% FTSE 100 6,564.10 +0.09% FTSE 250 15,837.69 +0.30% The FTSE 100 was more or less flat by midday on Friday after trading within a narrow ran

Read more
7 Feb 2014 11:08

STOCKS NEWS EUROPE-Tate bolstered by double JPMorgan upgrade

Shares in sweetener maker Tate & Lyle advance 2.1 percent, among the top risers on Britain's FTSE 100, with traders citing a double upgrade by JPMorgan, to "overweight" from "underweight", as the catalyst for the move. Trading volume in Tate is robust at around half of its 90-day daily aver

Read more
7 Feb 2014 11:02

UK WINNERS & LOSERS: AstraZeneca Recovers but Shire Slides

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Friday. ------- FTSE 100 - WINNERS Tate & Lyle, up 2.2%. The speciality food and bulk ingredients manufacturer has jumped after JPMorgan Cazenove upgraded its r

Read more
7 Feb 2014 10:04

UK BROKER RATINGS: Liberum Raises AstraZeneca To Top Pick

LONDON (Alliance News) - The following UK shares received analyst recommendations Friday morning and Thursday afternoon:
----------
FTSE 100
----------
S&P CAPITAL IQ RAISES ASTRAZENECA PRICE TARGET TO 3800 (3700) PENCE - 'HOLD'
----------
SO

Read more
7 Feb 2014 09:30

Friday broker round-up UPDATE

Acal: N+1 Singer initiates with a target price of 380p and a buy recommendation. AstraZeneca: Societe Generale ups target price from 3030p to 3126p, but still recommends selling. Barratt Developments: Deutsche Bank raises target price from 394p to 480p keeping a buy recommendation. Beazley: Canac

Read more

Quickpicks are a member only feature

Login to your account